Heart failure is a syndrome that results from the inability of the cardiac pump to function properly to ensure the metabolic demand of the body. Its affects more than 60 million of patients worldwide and is the only cardiac disease that continues to grow despite standard of care. There are HF subpopulations.

Hyponatremic acute heart failure

Hyponatremic acute heart failure (AHF) is a severe pathological condition with a poor prognosis and limited therapeutic options apart from fluid restriction. Hyponatremic AHF represents 20% of total acute heart failure patient population. In absence of effective treatments, most patients remain hyponatremic at discharge.

Chronically increased vasopressin plays a key role in the development of dilutional hyponatremia and AHF. Significant reduction of vasopressin is expected to normalize natremia and alleviate systemic congestion. This will translate into a decrease of hyponatremia-related disorders, length of patient hospitalization and subsequent risk of re-hospitalization and an improvement in quality of life.